Highlights
We monitor the growth and performance of our start-ups by collecting data on their funding rounds and other growth indicators. The endorsement by renowned academic institutions, the evaluation by our scientific Advisory Board, and the selection by our high-level Jury contribute to a very high survival rate of our winning start-ups. Many of them later become high-potential investment targets, poised to make a global impact in the years to come.
One of my personal highlights in 2022. Extremely well organised event with highly interesting participants.
Dominik Schumacher – Co-Founder & CEO of Tubulis, Finalist 2022
Some Success Stories
Repeated Success: In 2019, Alessandro Grillini-Kromm embarked on his journey as a Finalist from Falling Walls Lab with a pitch on his PhD research "Breaking the Wall of Neuro-Visual Diagnosis". In 2020, he founded Reyedar, a start-up that has developed an innovative system for detecting neurovisual disorders. In 2023, he also convinced the Falling Walls Venture Jury and was awarded Falling Walls Science Breakthrough of the Year 2023 in the Science Start-ups category. The company’s first product, the SONDA Screener, is now CE Certified and was officially launched in 2024.
Repeated Success: In 2019, Alessandro Grillini-Kromm embarked on his journey as a Finalist from Falling Walls Lab with a pitch on his PhD research "Breaking the Wall of Neuro-Visual Diagnosis". In 2020, he founded Reyedar, a start-up that has developed an innovative system for detecting neurovisual disorders. In 2023, he also convinced the Falling Walls Venture Jury and was awarded Falling Walls Science Breakthrough of the Year 2023 in the Science Start-ups category. The company’s first product, the SONDA Screener, is now CE Certified and was officially launched in 2024.
Acquired by Partner: T3 Pharmaceuticals was awarded Falling Walls Science Breakthrough of the Year in the Science Start-ups category in 2018. Following initial investments and ongoing support from our valued partner Boehringer Ingelheim Venture Fund, the company was acquired by Boehringer Ingelheim in 2023 for 450 million CHF. Their innovative cancer therapy platform harnesses the natural behaviours of live bacteria and is now undergoing clinical studies.
Acquired by Partner: T3 Pharmaceuticals was awarded Falling Walls Science Breakthrough of the Year in the Science Start-ups category in 2018. Following initial investments and ongoing support from our valued partner Boehringer Ingelheim Venture Fund, the company was acquired by Boehringer Ingelheim in 2023 for 450 million CHF. Their innovative cancer therapy platform harnesses the natural behaviours of live bacteria and is now undergoing clinical studies.
Science Breakthroughs
Discover the Science Breakthroughs of the past years in our Science Start-up category.